Abstract 5253
Background
Aberrant miRNA expression has been associated with DNA damage response (DDR) pathways that modulate tumor response to platinum agents. We assessed the expression of miR-21, miR-128, mir-155 and miR-181 involved in DDR pathways, in the plasma of metastatic non- small cell lung cancer (mNSCLC) patients receiving 1st-line platinum-based chemotherapy (CMT) and the levels were correlated with patients’ outcomes. We also performed bioinformatics analysis to identify putative target genes of the above miRNAs.
Methods
Plasma samples were obtained from patients (n = 128) before 1st-line CMT. miR-21, miR-128, miR-155 and miR-181 expression levels were assessed by RT-qPCR and expression was classified as high or low according to the median values. Pathway analysis was performed by Diana-Tarbase algorithm.
Results
Mir-128 (p < 0.001), miR-155 (p < 0.001) and miR-181 (p = 0.012) were higher in mNSCLC patients compared to healthy donors. Patients with high miR-128 and miR-155 expression had shorter overall survival (OS) (p = 0.028 and p = 0.035, respectively). In multivariate analysis performance status of 2 and high miR-128 expression independently predicted for shorter OS in the whole group of patients (p = 0.003 and p = 0.026, respectively). No differences in miRNA expression were revealed among patients with adenocarcinoma (n = 79) and squamous carcinoma (SCC; n = 41). However, in the SCC subgroup, besides miR-128 and miR-155, high miR-21 and miR-181 expression were associated with shorter OS (p = 0.021, p = 0.015, p = 0.004 and p = 0.028, respectively). In multivariate analysis, miR-155 high expression independently predicted for decreased OS (p = 0.004). Integrated function and pathway analysis on miRNA predicted genes revealed that pathways related to cancer, cell cycle, apoptosis and drug resistance were significantly enriched.
Conclusions
Differential expression levels of DDR related miRNAs are encountered in mNSCLC patients before 1st-line platinum-based CMT and independently predict patients’ outcomes. The association of miR-155 with the prognosis of patients with SCC merits further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
HESMO.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4596 - A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis (MBM) (POLARIS)
Presenter: Michael Davies
Session: Poster Display session 3
Resources:
Abstract
1891 - Continuation of annual screening mammograms and breast-cancer mortality in women over 70
Presenter: Xabier Garcia De Albeniz
Session: Poster Display session 3
Resources:
Abstract
5587 - Introducing standardized medical procedure and dynamic decision support program in precision oncology for the community of practice
Presenter: Istvan Petak
Session: Poster Display session 3
Resources:
Abstract
4757 - Effectively using primary care givers in oncology care through capacity building, task sharing and techno-mentoring.
Presenter: Dinesh Pendharkar
Session: Poster Display session 3
Resources:
Abstract
4497 - A single institution review of capecitabine related acute admissions and cost analysis
Presenter: Gemma Dart
Session: Poster Display session 3
Resources:
Abstract
2187 - Health status of middle-aged and older cancer survivors in China: results from the China Health and Retirement Longitudinal Study (CHARLS)
Presenter: Jiarui Li
Session: Poster Display session 3
Resources:
Abstract
5101 - Crossed looks on lung cancer perception and knowledge from general public and physicians in France: results of a two-fold survey
Presenter: Céline Mascaux
Session: Poster Display session 3
Resources:
Abstract
4354 - Knowledge and perception of clinical trials (CTs) and attitude towards participation among Polish oncological patients - A pilot survey
Presenter: Artur Kotowski
Session: Poster Display session 3
Resources:
Abstract
3499 - Achieving best possible cancer treatment outcomes in care pathways through benchmarking; ABC-Benchmarking
Presenter: Anke Wind
Session: Poster Display session 3
Resources:
Abstract
2270 - Impact of 10-day Fulbright Specialist Program (FSP) and Project Pink Blue (PPB) Education Sessions on Medical Oncology knowledge among Doctors that treat cancer in Nigeria
Presenter: Mike Martin
Session: Poster Display session 3
Resources:
Abstract